You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
大行評級|大摩:維持石藥集團“增持”評級 第三季業績遠不及預期
格隆匯 11-01 11:12

摩根士丹利發表報吿,石藥集團第三季初步盈利按年大跌50.6%至7.55億元,遠不及預期;管理層將盈利倒退歸咎於成品藥銷售遠低於預期,下降幅度為19%,情況遠差於該行預期的下跌3%,預計市場會將石藥今年及之後的預測調低。大摩維持石藥“增持”評級,目標價6.9港元。

報吿提到,石藥上季腫瘤藥物銷售按年下降31%,較大摩預期的下跌20%更差,因多美素(Duomeisu)等藥物受到的中央採購的影響超出預期。至於心血管藥品方面,銷售下跌27%,大摩原預期為增長3%,主要因為玄寧(Xuanning)的銷售持續下滑。而中樞神經系統藥品方面,銷售下降16%,大摩原預計為增長2%,受累於丁苯(酉太)在醫院的銷售大幅減少。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account